---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278174004.md"
description: "Replimune Group Inc. (REPL) rose 12% in after-hours trading, and Capricor Therapeutics Inc. (CAPR) rose 7.5%"
datetime: "2026-03-06T22:08:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278174004.md)
  - [en](https://longbridge.com/en/news/278174004.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278174004.md)
---

# 

Replimune Group Inc. (REPL) rose 12% in after-hours trading, and Capricor Therapeutics Inc. (CAPR) rose 7.5%

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [FDA issues complete response letter to Replimune’s RP1 for melanoma](https://longbridge.com/en/news/282511585.md)
- [Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA](https://longbridge.com/en/news/282576241.md)
- [FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short](https://longbridge.com/en/news/282376421.md)
- [Replimune Disputes FDA Rejection of Skin Cancer Treatment, Criticizes Review Process](https://longbridge.com/en/news/282393660.md)